Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Liabilities and Shareholders Equity (2016 - 2025)

IGC Pharma (IGC) has disclosed Liabilities and Shareholders Equity for 15 consecutive years, with $9.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity fell 6.04% to $9.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $35.5 million, a 15.7% decrease, with the full-year FY2025 number at $8.7 million, down 11.66% from a year prior.
  • Liabilities and Shareholders Equity was $9.7 million for Q3 2025 at IGC Pharma, up from $7.9 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $35.9 million in Q1 2021 to a low of $7.9 million in Q2 2025.
  • A 5-year average of $18.7 million and a median of $16.5 million in 2023 define the central range for Liabilities and Shareholders Equity.
  • Peak YoY movement for Liabilities and Shareholders Equity: increased 29.49% in 2021, then tumbled 43.9% in 2023.
  • IGC Pharma's Liabilities and Shareholders Equity stood at $31.3 million in 2021, then plummeted by 35.85% to $20.1 million in 2022, then crashed by 43.9% to $11.3 million in 2023, then fell by 19.37% to $9.1 million in 2024, then rose by 7.33% to $9.7 million in 2025.
  • Per Business Quant, the three most recent readings for IGC's Liabilities and Shareholders Equity are $9.7 million (Q3 2025), $7.9 million (Q2 2025), and $8.7 million (Q1 2025).